药监局新规开路，中国脑机接口「弯道超车」的机会来了！

TL;DR - China’s drug regulator issued classification and naming guidelines for brain–computer-interface medical devices, clarifying regulatory boundaries and recognizing non-invasive BCI rehabilitation systems. The rules could accelerate clinical adoption and commercialization of lower-cost, AI-enabled BCI products.

• Non-invasive BCIs combine sensitive electrodes, signal processing, and AI-based intent decoding to overcome weak, noisy EEG signals.
• Rehabilitation for stroke, spinal-cord injury, and limb impairment is the most mature application, with reimbursement frameworks also emerging.
• China’s electronics manufacturing and AI ecosystems may favor scalable non-invasive devices over costlier, higher-risk implants.
• Companies are extending BCI platforms from clinical rehabilitation into prosthetics, attention training, sleep management, consumer electronics, and robot control.